Microglial activation correlates with severity in Huntington disease: A clinical and PET study

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Standard

Microglial activation correlates with severity in Huntington disease : A clinical and PET study. / Pavese, N.; Gerhard, A.; Tai, Y. F.; Ho, A. K.; Turkheimer, F.; Barker, R. A.; Brooks, D. J.; Piccini, P.

In: Neurology, Vol. 66, No. 11, 01.06.2006, p. 1638-1643.

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

Harvard

Pavese, N, Gerhard, A, Tai, YF, Ho, AK, Turkheimer, F, Barker, RA, Brooks, DJ & Piccini, P 2006, 'Microglial activation correlates with severity in Huntington disease: A clinical and PET study', Neurology, vol. 66, no. 11, pp. 1638-1643. https://doi.org/10.1212/01.wnl.0000222734.56412.17

APA

Pavese, N., Gerhard, A., Tai, Y. F., Ho, A. K., Turkheimer, F., Barker, R. A., Brooks, D. J., & Piccini, P. (2006). Microglial activation correlates with severity in Huntington disease: A clinical and PET study. Neurology, 66(11), 1638-1643. https://doi.org/10.1212/01.wnl.0000222734.56412.17

CBE

MLA

Vancouver

Author

Pavese, N. ; Gerhard, A. ; Tai, Y. F. ; Ho, A. K. ; Turkheimer, F. ; Barker, R. A. ; Brooks, D. J. ; Piccini, P. / Microglial activation correlates with severity in Huntington disease : A clinical and PET study. In: Neurology. 2006 ; Vol. 66, No. 11. pp. 1638-1643.

Bibtex

@article{58c06f240c3a4a8c9a05a8ccf83e613f,
title = "Microglial activation correlates with severity in Huntington disease: A clinical and PET study",
abstract = "BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [C](R)-PK11195 PET, a marker of microglia activation, and [C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal [C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These [C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.",
author = "N. Pavese and A. Gerhard and Tai, {Y. F.} and Ho, {A. K.} and F. Turkheimer and Barker, {R. A.} and Brooks, {D. J.} and P. Piccini",
year = "2006",
month = jun,
day = "1",
doi = "10.1212/01.wnl.0000222734.56412.17",
language = "English",
volume = "66",
pages = "1638--1643",
journal = "Neurology",
issn = "0028-3878",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "11",

}

RIS

TY - JOUR

T1 - Microglial activation correlates with severity in Huntington disease

T2 - A clinical and PET study

AU - Pavese, N.

AU - Gerhard, A.

AU - Tai, Y. F.

AU - Ho, A. K.

AU - Turkheimer, F.

AU - Barker, R. A.

AU - Brooks, D. J.

AU - Piccini, P.

PY - 2006/6/1

Y1 - 2006/6/1

N2 - BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [C](R)-PK11195 PET, a marker of microglia activation, and [C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal [C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These [C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.

AB - BACKGROUND: Huntington disease (HD) is characterized by the progressive death of medium spiny dopamine receptor bearing striatal GABAergic neurons. In addition, microglial activation in the areas of neuronal loss has recently been described in postmortem studies. Activated microglia are known to release neurotoxic cytokines, and these may contribute to the pathologic process. METHODS: To evaluate in vivo the involvement of microglia activation in HD, the authors studied patients at different stages of the disease using [C](R)-PK11195 PET, a marker of microglia activation, and [C]raclopride PET, a marker of dopamine D2 receptor binding and hence striatal GABAergic cell function. RESULTS: In HD patients, a significant increase in striatal [C](R)-PK11195 binding was observed, which significantly correlated with disease severity as reflected by the striatal reduction in [C]raclopride binding, the Unified Huntington's Disease Rating Scale score, and the patients' CAG index. Also detected were significant increases in microglia activation in cortical regions including prefrontal cortex and anterior cingulate. CONCLUSIONS: These [C](R)-PK11195 PET findings show that the level of microglial activation correlates with Huntington disease (HD) severity. They lend support to the view that microglia contribute to the ongoing neuronal degeneration in HD and indicate that [C](R)-PK11195 PET provides a valuable marker when monitoring the efficacy of putative neuroprotecting agents in this relentlessly progressive genetic disorder.

UR - http://www.scopus.com/inward/record.url?scp=33745637954&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000222734.56412.17

DO - 10.1212/01.wnl.0000222734.56412.17

M3 - Journal article

C2 - 16769933

AN - SCOPUS:33745637954

VL - 66

SP - 1638

EP - 1643

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 11

ER -